Publications by authors named "H Czajka"
Article Synopsis
- Respiratory syncytial virus (RSV) is primarily a pathogen for infants but can also severely affect older adults, particularly those with pre-existing health issues; traditionally, prevention focused on passive immunization with palivizumab for high-risk infants.
- * The COVID-19 pandemic has led to changes in RSV patterns, such as shifts in seasonality and increased cases in older age groups, highlighting the urgent need for new prevention and treatment strategies.
- * Recently, two protein-based vaccines for adults and older individuals have been approved, along with a new monoclonal antibody named nirsevimab for pediatric use, marking significant advancements in RSV prevention methods.
Preterm newborns are babies born before the end of the 36th week of gestational life. They are at increased risk of infection and death from infectious diseases. This is due, among other things, to the immaturity of the immune system and the long hospitalisation period.
View Article and Find Full Text PDFBackground: Meningococcal serogroups A, B, C, W, and Y cause nearly all meningococcal disease, and comprehensive protection requires vaccination against all five serogroups. We aimed to assess the immunogenicity and safety of a pentavalent MenABCWY vaccine comprising two licensed vaccines-meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) and a quadrivalent meningococcal serogroup ACWY tetanus toxoid conjugate vaccine (MenACWY-TT)-compared with two doses of MenB-FHbp and a single dose of quadrivalent meningococcal serogroup ACWY CRM-conjugate vaccine (MenACWY-CRM) as the active control. We previously reported the primary safety and immunogenicity data relating to the two-dose MenB-FHbp schedule.
View Article and Find Full Text PDFThe Bacillus Calmette-Guérin (BCG) vaccine has been in use for over 100 years. It protects against severe, blood-borne forms of tuberculosis. Observations indicate that it also increases immunity against other diseases.
View Article and Find Full Text PDFBackground: Safe and effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in young children.
Methods: We conducted a phase 1 dose-finding study and are conducting an ongoing phase 2-3 safety, immunogenicity, and efficacy trial of the BNT162b2 vaccine in healthy children 6 months to 11 years of age. We present results for children 6 months to less than 2 years of age and those 2 to 4 years of age through the data-cutoff dates (April 29, 2022, for safety and immunogenicity and June 17, 2022, for efficacy).